Telix Pharmaceuticals was created to deliver on the promise of nuclear medicine
The field of nuclear medicine has historically lacked clinical momentum and commitment to late-stage product development. Our goal is to rectify this for the benefit of patients.
Activities Report and Appendix 4C for September 2021 Quarter
Melbourne (Australia) – 21 October 2021. Telix provides its Appendix 4C and accompanying Activities Report for the quarter ended 30 September 2021.
Telix Satellite Symposium at European Association of Nuclear Medicine Annual Congress 2021
15 October 2021 – Clinical Spotlight | Telix Satellite Symposium at the European Association of Nuclear Medicine 2021 Virtual Conference.
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
Potential Indication Expansion for Telix’s Core Kidney Cancer Theranostic Program Melbourne (Australia) and Liège (Belgium) – 5 October 2021. Telix announces...
Telix Establishes Commercial Hub in Geneva, Switzerland
Melbourne (Australia) and Geneva (Switzerland) – 4 October 2021. Telix announces that it has established a new commercial hub in...